Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 7/20 | 0.41 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.41 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.38 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | DRD4 | P21917 | 1/20 | 0.37 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 2/20 | 0.33 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13254845 | 1.00 | NPC1 (0.51) | NPC1RAB9ASMN1; SMN2DPP7POLB | |
| SCHEMBL4445192 | 1.00 | NPC1 (0.51) | NPC1RAB9ASMN1; SMN2DPP7POLB | |
| SCHEMBL10757334 | 0.98 | NPC1 (0.50) | NPC1RAB9ASMN1; SMN2DPP7POLB | |
| SCHEMBL10752905 | 0.96 | DPP7 (0.51) | NPC1RAB9ASMN1; SMN2DPP7POLB | |
| SCHEMBL10591026 | 0.96 | DPP7 (0.51) | NPC1RAB9ASMN1; SMN2DPP7POLB | |
| SCHEMBL14740663 | 0.93 | NPC1 (0.45) | NPC1RAB9ASMN1; SMN2DPP7POLB | |
| SCHEMBL2824467 | 0.91 | NPC1 (0.56) | NPC1RAB9ASMN1; SMN2DPP7POLB | |
| SCHEMBL1419834 | 0.87 | NPC1 (0.47) | NPC1RAB9ASMN1; SMN2DPP7POLB | |
| SCHEMBL3169796 | 0.87 | NPC1 (0.51) | NPC1RAB9ASMN1; SMN2DPP7POLB | |
| SCHEMBL6214888 | 0.86 | DPP7 (0.39) | NPC1RAB9ASMN1; SMN2DPP7POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 499 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630588-B2 | Bicyclic peptide ligands specific for CD137 | BICYCLETX LIMITED (GB) | 2026-05-19 | — | — | US | claimed |
| US-20250325672-A1 | ANTI-INFECTIVE BICYCLIC PEPTIDE LIGANDS | BICYCLE TX LTD (GB) | 2025-10-23 | — | — | US | claimed |
| US-20250059236-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR CD137 | BICYCLETX LIMITED (GB) | 2025-02-20 | — | — | US | claimed |
| EP-4464715-A2 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NECTIN-4 | BicycleTx Limited (GB) | 2024-11-20 | — | — | EP | claimed |
| US-20240083944-A1 | ANTI-INFECTIVE BICYCLIC PEPTIDE LIGANDS | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2024-03-14 | — | — | US | claimed |
| EP-4274839-A1 | ANTI-INFECTIVE BICYCLIC PEPTIDE LIGANDS | BicycleTx Limited (GB) | 2023-11-15 | — | — | EP | claimed |
| EP-4274841-A1 | ANTI-INFECTIVE BICYCLIC PEPTIDE LIGANDS | BicycleTx Limited (GB) | 2023-11-15 | — | — | EP | claimed |
| CN-117062826-A | Antiinfective bicyclic peptide ligands | 拜斯科技术开发有限公司 | 2023-11-14 | — | — | CN | claimed |
| CN-117043176-A | Antiinfective bicyclic peptide ligands | 拜斯科技术开发有限公司 | 2023-11-10 | — | — | CN | claimed |
| US-20230127559-A1 | PEPTIDE ANALOGS AND USE OF SAME IN TREATING DISEASES, DISORDERS OR CONDITIONS ASSOCIATED WITH MUTANT P53 PROTEIN | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2023-04-27 | — | — | US | claimed |
| EP-2120983-A2 | NOVEL ANTI-MICROBIAL PEPTIDOMIMETIC COMPOUNDS AND METHODS TO CALCULATE ANTI-MICROBIAL ACTIVITY | The United States of America, as represented by The Secretary of the Army, on behalf of The Walter Reed Army Institute of Research (US) | 2009-11-25 | — | — | EP | claimed |
| US-20090069574-A1 | Process for the synthesis of an ace inhibitor | CIPLA LIMITED (IN) | 2009-03-12 | — | — | US | claimed |
| EP-1995256-A1 | EPHA2 T-cell epitope agonists and uses therefor | University of Pittsburgh of the Commonwealth System of Higher Education (US) | 2008-11-26 | — | — | EP | claimed |
| WO-2008079314-A2 | NOVEL ANTI-MICROBIAL PEPTIDOMIMETIC COMPOUNDS AND METHODS TO CALCULATE ANTI-MICROBIAL ACTIVITY | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE ARMY, ON BEHALF OF WALTER REED ARMY INSTITUTE OF RESEARCH (US) | 2008-07-03 | — | — | WO | claimed |
| EP-1651671-A2 | EPHA2 T-CELL EPITOPE AGONISTS AND USES THEREFOR | UNIVERSITY OF PITTSBURGH OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2006-05-03 | — | — | EP | claimed |
| US-20060019899-A1 | EphA2 T-cell epitopes and uses therefor | UNIVERSITY OF PITTSBURGH (US) | 2006-01-26 | — | — | US | claimed |
| US-20050048550-A1 | EphA2 T-cell epitope agonists and uses therefor | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2005-03-03 | — | — | US | claimed |
| WO-2005012350-A2 | EPHA2 T-CELL EPITOPE AGONISTS AND USES THEREFOR | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2005-02-10 | — | — | WO | claimed |
| US-6258815-B1 | HETEROCYCLIC COMPOUNDS | ASTA MEDICA AKTIENGESELLSCHAFT (DE) | 2001-07-10 | — | — | US | claimed |
| US-6251932-B1 | AN INDOLE DERIVATIVE IN A CARRIER-IMMOBILIZED FORM FOR BINDING PATHOGENIC IMMUNOPHILINS FROM THE BODY FLUID; USEFUL AS AN IMMUNOSUPRESSANT | ASTA MEDICA AG (DE) | 2001-06-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250325672-A1 | ANTI-INFECTIVE BICYCLIC PEPTIDE LIGANDS | ACE2, SARS1, TMPRSS2 | NPC1 2988/4885RAB9A 3663/4885SMN1; SMN2 4777/4885 |
| US-12630588-B2 | Bicyclic peptide ligands specific for CD137 | PTMS, IL36G, HLA-A | NPC1 2569/4885RAB9A 691/4885SMN1; SMN2 4497/4885 |
| US-20090069574-A1 | Process for the synthesis of an ace inhibitor | ACE, ACE2, AGTR1 | NPC1 2900/4885RAB9A 3582/4885SMN1; SMN2 4312/4885 |
| US-20240083944-A1 | ANTI-INFECTIVE BICYCLIC PEPTIDE LIGANDS | ACE2, SARS1, TMPRSS2 | NPC1 3987/4885RAB9A 4056/4885SMN1; SMN2 4573/4885 |
| US-20250059236-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR CD137 | CD2BP2, CD40, SDC1 | NPC1 1129/4885RAB9A 2479/4885SMN1; SMN2 3096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.